HCP5 and acute myeloid leukemia: According to the findings, the high expression of human histocompatibility leukocyte antigen (HLA) complex P5 (HCP5) lncRNA in AML patients is a risk factor of adverse prognosis [HR = 5.090, 95% CI (1.993, 12.996), and p < 0.001], whereas the low expression of maternally expressed gene 3 (MEG3) lncRNA is a protective prognostic factor [HR = 0.487, 95% CI (0.284 and 0.836), and p = 0.009] (Figure 3C).